Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients

Disease Markers

Volumn 32, Issue 1, 2012, Pages 43-50

  Masebe, Tracy Madimabi ^a   Bessong, Pascal Obong ^a   Nwobegahay, Julius ^a   Ndip, Roland Ndip ^b,c   Meyer, Debra ^d  

^a UNIVERSITY OF VENDA   (South Africa)

^b UNIVERSITY OF FORT HARE   (South Africa)

^c UNIVERSITY OF BUEA   (Cameroon)

^d UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

CYP2B6; HIV; MDR1; polymorphisms; South Africa

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BASE PAIRING; DNA POLYMORPHISM; DRUG METABOLISM; DRUG TRANSPORT; EXON; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIROLOGY; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84856630074     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2012-0859     Document Type: Article

References (36)

1. G. Severino amd M.D. Zompo, Adverse drug reactions, Role of Pharmacogenomics, Pharmacological Research 49 (2004), 363-373. (Pubitemid 38175334)
2. V. Tozzi, Pharmacogenetics of antiretrovirals, Antiviral Research 85 (2010), 190-200.
3. R.L. Oostendorp, J.H. Beijen and J.H.M. Schellens, The biological and clinical role of drug transporter at the intestinal barrier, Cancer Treatment Review 35 (2009), 137-147.
4. E. Schaeffeler, E. Eichelbaum, M. Brinkmann, U. Penger, A. Asante-Poku, M.U. Zanger and M. Schwab, Frequency of C3435T polymorphism of MDR1 gene in African people, Lancet 358 (2001), 383-384. (Pubitemid 32739101)
5. Department of Health, The South African antiretroviral treatment guidelines, Republic of South Africa (2010), 1-6.
6. J. King and J.A. Aberg, Clinical impact of patient population differences and genomic variation in efavirenz therapy, AIDS 22 (2008), 1709-1717.
7. M. Ingelman-Sundberg, S.C. Sim, A. Gomez and C. Rodr-iguez-Antona, Influence of cytochrome P450 polymorphisms on drug therapies, pharmacogenetic, pharmacoepigenetic and clinical aspects, Pharmacology and Therapeutics 116 (2007), 496-452.
8. A. Saitoh, E. Sarles, E. Capparelli, F. Aweeka, A. Kovacs, S.K. Burchett, A. Wiznia, S. Nachman, T. Fenton and S.A. Spector, CYP2B6 genetic variants are associated with nevirapine and clinical response in HIV-1 infected children, AIDS 27 (2007), 2191-2199. (Pubitemid 350287217)
9. D. Haas, L.M. Smeaton, R.W. Shafer, G.K. Robbins, G.D. Morse, L. Labbe, G.R. Wilkinson, D.B. Clifford, R.T. D'Aquila, V. De Gruttola, R.B. Pollard, T.C. Merigan, M.S. Hirsch, A.L. George, J.P. Donahue, R.B. Kim, Pharmaco-genetics of long-term responses to antiretrovirals containing Efavirenz and/or Nelfinavir: an adult AIDS clinical trials group study, Journal of Infectious Diseases 192 (2005), 1931-1942. (Pubitemid 41681891)
10. S. Rodriguez-Novoa, P. Barreiro, A. Rendon, I. Jimenez-Nacher, J. Gonzalez-Lahoz and V. Soriano, Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects, Clinical Infectious Diseases 40 (2005), 1358-1361. (Pubitemid 40570249)
11. S.T. Sadiq, S. Fredericks, S.H. Khoo, P. Rice and D.W. Holt, Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance, AIDS 19 (2005), 1716-1717. (Pubitemid 41502696)
12. H.J. Ribaudo, D.W. Haas, C. Tierney, R.B. Kim, G.R. Wikin-son, R. Gulick, D.B. Clifford, C. Marzolini, C.V. Fletcher, K.T. Tashima and D.R. Kuritzkes, Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study, Clinical Infectious Diseases 42 (2006), 401-407. (Pubitemid 43122320)
13. C. Nyakutira, D. Roshammar, E. Chigutsa, P. Chonzi, M. Ashton, C. Nhachi and C. Masimirembwa, High prevalence of the CYP2B6 516→T(6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe, European Journal of Clinical Pharmacology 64 (2008), 357-365.
14. S.R. Penzak, P. Mugyenyi, F. Mbamanya, V. Natarajan, R.M. Alfaro, C. Kityo, E. Formentin and E. Masur, Cy-tochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda, HIV Medicine 8 (2007), 86-91. (Pubitemid 46390844)
15. J. Whetham, S. Charalambous, J. Lewis, K. Fielding, H. McIlleron, A. Walley, G.J. Churchyard and A.D. Grant, Efavirenz dose reduction based on CYP2B6 genotype is not supported by data from men in South Africa, HIV Medicine 9 (2008), 21.
16. A, Owen, C. Goldring, P. Morgan, D. Chadwick, B.K. Park and M. Pirmohamed, Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver, British Journal of Clinical Pharmacology 59 (2005), 365-370.
17. C.G.L. Lee and M.M. Gottseman, HIV-1 Protease inhibitors and the MDR1 drug transporter, Journal of Clinical Investigation 101 (1998), 287-288. (Pubitemid 28067323)
18. P. Chelule, M. Gordon and T. Palanee, MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa, Clinical Pharmacology and Therapeutics 74 (2003), 195-196. (Pubitemid 36951818)
19. Q. Dong, B. Xu, Y. Tan, Z. Liu, L. Tian, B. Zhang, C. Lin, H. Kung, J.J.Y. Sung and M. He, The genetic variability of MDR1 C3435T polymorphisms in four Southern Chinese populations, Biomedicine and Pharmacotherapy 63 (2009), 658-662.
20. M.L. Bernal, B. Sinues, A. Fanlo and E. Mayayo, Frequency Distribution of C3435T Mutation in Exon 26 of the MDR1 Gene in a Spanish Population, Therapeutic Drug Monitoring 25 (2003), 107-111. (Pubitemid 36139834)
21. M, Pirmohamed and J. Back, The pharmacogenomics of HIV, Pharmacogenomics Journal 1 (2001), 243-253.
22. D. Haas, Pharmacogenomics and HIV Therapeutics, Journal of Infectious Diseases 191 (2005), 1397-1400. (Pubitemid 40563348)
23. Y. Li, Y. Wang, Y. Li and L. Yang, MDR1 gene polymorphisms and clinical relevance, Acta Genetica Sinica 33 (2006), 93-104. (Pubitemid 43267147)
24. C. Balram, A. Sharma, C. Sivathasan and E.J.D. Lee, Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: Phenotypic-genotypic correlates, Journal of Clinical Pharmacology 56 (2003), 78-83. (Pubitemid 36886491)
25. C. Chen, D. Clark, K. Ueda, I. Pastan, M.M. Gottesman and I.B. Roninson, Genomic organization of the Human multidrug resistance gene and origin of P-glycoproteins, Journal of Biological Chemistry 265 (1990), 506-514.
26. N. Ariyoshi, M. Miyazaki, K. Toide, Y. Sawamura and T. Kamataki, A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactiva-tion, Biochemical and Biophysical Research Communications 281 (2001), 1256-1260. (Pubitemid 32924554)
27. T.R. Cressey and M. Lallemant, Pharmacogenetics of an-tiretroviral drugs for the treatment of HIV-infected patients: An update, Infections, Genetics and Evolution 7 (2007), 333-342. (Pubitemid 46187499)
28. K.E. Estes, K.H. Busse and S.R. Penzak, Pharmacogenetic considerations in the management of HIV infection, Journal of Pharmacy Practice 20 (2007), 234-245.
29. K.L. Fung and M.M. Gottesman, A synonymous polymorphism in a common MDR (ABCB) haplotype shapes protein function, Biochimica Biophysica Acta 1794 (2009), 860-871.
30. M.M. Ameyaw, F. Regateiro, X. Liu, M. Tariq, A. Mobarek, N. Thornton, G.O. Folayan, J. Githang'a, A. Indalo, D. Ofori-Adjei, D.A. Price-Evans and H.L. McLeod, MDR1 pharma-cogenetics, frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity, Pharmacogenetics 11 (2001), 217-221. (Pubitemid 32319871)
31. J. Fellay, C. Marzolini, E.R. Meaden, D.J. Back, T. Buclin, J. Chave, L.A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A.H. Schinkel, P. Vernazza and C.B. Eap, A. Telenti for the Swiss HIV cohort study, Response to antiretroviral treatment in HIV-1 Infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetic study, Lancet 359 (2002), 31-36.
32. G. Ramachandran, K. Ramesh, A.K.H. Kumar, P. Kumar, K. Ramesh, S. Anitha, G. Narendran, P. Menon, C. Go-mathi and S. Swaminathan, Association of high frequency of CYP2B6 G516T polymorphism among ethnic South Indian HIV-infected patients with elevated plasma efavirenz and nevi-rapine, Journal of Antimicrobial Chemotherapy 63 (2009), 841-843.
33. K. Tsuchiya, H. Gatanaga, N. Tachikawa, K. Teruya, Y. Kikuchi, M. Yoshino, T. Kuwahara, T. Shirasaka, S. Kimura and S. Oka, Homozygous CYP2B66 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens, Biochemical and Biophysical Research Communications 319 (2004), 1322-1326. (Pubitemid 38759555)
34. B.A. Ward, J.C. Gorski, D.R. Jones, S.D. Hall, D.A. Flockhart and Z. Desta, The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity, Journal of Pharmacology and Experimental Therapeutics 306 (2003), 287-300. (Pubitemid 36734384)
35. P.F Smith, R. DiCenzo and G.D. Morse, Clinical pharma-cokinetics of non-nucleoside reverse transcriptase inhibitors, Clinical Pharmacokinetics 40 (2001), 893-905. (Pubitemid 34066687)
36. S. Uttayamakul, S. Likanonsakul, W. Manosuthi, N. Wich-ukchinda, T. Kalambaheti, E.E. Nakayama, T. Shioda and S. Khusmith, Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults, AIDS Research and Therapy 7 (2010), 8.